Open AccessMicroribonucleic acids and gastric cancer
Author(s) -
Ma YingYu,
Tao HouQuan
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2011.02185.x
Subject(s) - cancer , microrna , carcinogenesis , epigenetics , suppressor , cancer research , gene , biology , translation (biology) , disease , pathogenesis , bioinformatics , medicine , genetics , immunology , messenger rna
Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein‐coding proto‐oncogenes and tumor‐suppressor genes. Microribonucleic acids (miR) are a recently‐described class of genes encoding small non‐coding RNA molecules, which primarily act by downregulating the translation of target mRNA. It has become apparent that miR are also key factors in cancer, playing both oncogenic and tumor‐suppressing roles in gastric cancer. Recent studies have shown that a substantial number of miR show differential expression in gastric cancer tissues, and they are turning out to be just like any other regulatory gene. In this connection, miR dysregulation are reported to be associated with incidence, early diagnosis and prognosis of gastric cancer. Therefore, investigation of the biological aspects of miR dysregulation might help us better understand the pathogenesis of gastric cancer and promote the development of miR‐directed therapeutics against this deadly disease. The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR‐21, miR‐106a and miR‐17), tumor suppressor miR (e.g. miR‐101, miR‐181, miR‐449, miR‐486, let‐7a ) and controversial roles of miR (e.g. miR‐107, miR‐126) for gastric cancer. In addition, their potential clinical applications and prospects in gastric cancer, such as biomarkers and clinical therapy tools, are also briefly discussed. ( Cancer Sci 2012; 103: 620–625)